The Peptide Nook

Eloralintide

In plain English

Eloralintide copies amylin, a hormone released with insulin after meals that makes you feel full sooner. It is taken once a week and is being developed by Eli Lilly as a weight-loss medicine on its own or alongside GLP-1 medicines.

What it's used for

  • Weight loss
  • Combination with GLP-1 medicines (being studied)

Benefits

In human studies, eloralintide produced average weight loss of about 9.5–20.1% over 48 weeks, depending on dose, compared with 0.4% for placebo, in its phase 2 trial.

  • Feeling full sooner and eating smaller meals
  • Weight loss comparable to some GLP-1 medicines

How it works

In simple terms: amylin is a “slow down, you’ve eaten enough” signal, and eloralintide copies it.

It activates amylin receptors in the brainstem, reducing meal size and slowing stomach emptying. It is selective for amylin receptors, which may limit the nausea seen with older amylin drugs.

Development history

  • 2020s: Developed by Eli Lilly.
  • 2025: Phase 2 results presented.
  • Next: Phase 3 trials planned.

Typical protocols

Educational information only, not medical advice. The information below describes how this peptide has been used in research, on prescription labels or by users. It is not a recommendation. Talk to a qualified healthcare professional before starting, stopping or changing anything.

These doses come from the phase 2 trial.

Use Dose Frequency
Studied range 1–9 mg, reached by slow increases Weekly

Cycling

Studied as a continuous treatment.

Administration options

Subcutaneous injection once a week.

Reconstitution and dosing calculator

Vials of powder are mixed with bacteriostatic water: for example, 10 mg with 2 mL gives 5 mg per mL.

1Peptide in the vial

The total amount printed on the vial label.

2Bacteriostatic water added

More water makes each dose a bigger, easier-to-measure draw. It does not change how much peptide is in the vial.

3Dose per injection

Use the dose from your protocol or your clinician. 1 mg = 1,000 mcg.

4Your syringe

All three are U-100 insulin syringes: 100 units = 1 mL. Smaller barrels make small doses easier to read.

Draw your syringe to

– units

Volume to draw
–
Concentration
–
Each unit holds
–
Doses per vial
–
Show the math

    This tool does arithmetic only. It does not choose a dose or confirm that any substance is right for you. Double-check every result against your syringe and your clinician’s instructions.

    Side effects and safety

    • Most common: nausea and fatigue, mostly mild and early.
    • Vomiting and reduced appetite.
    • Long-term safety is still being studied.
    • Avoid during pregnancy.

    Common stacks

    GLP-1 medicines such as tirzepatide: combinations are being studied.

    Storage

    Powder: refrigerate. After mixing: refrigerate at 2–8 °C and use within about 4 weeks.

    Compare with

    • Cagrilintide: another long-acting amylin analog (from Novo Nordisk), paired with semaglutide in CagriSema.
    • GLP-1 medicines: a different fullness pathway.

    Frequently asked questions

    Eloralintide or cagrilintide?

    Both copy amylin and are taken weekly. Eloralintide is Lilly’s, studied alone and with GLP-1 drugs; cagrilintide is Novo Nordisk’s, best known paired with semaglutide.

    References

    1. Eli Lilly and Company. Eloralintide phase 2 results. Presented at ObesityWeek 2025.
    Educational information only. Not medical advice. Always consult a qualified healthcare professional.

    More posts